Group 1 - The core viewpoint of the news is the successful listing of Changfeng Pharmaceutical Co., Ltd. on the Hong Kong Stock Exchange, facilitated by ICBC International, highlighting the company's growth in the healthcare sector [1] - The issuance involved 41,198,000 shares at a final price of HKD 14.75 per share, raising approximately HKD 610 million (around USD 78 million) [1] - This project reflects ICBC International's commitment to promoting high-quality development in the healthcare industry and showcases its strength in serving major industry leaders [1] Group 2 - Changfeng Pharmaceutical focuses on the research, production, and commercialization of inhalation technology and drugs, specifically targeting respiratory diseases [2] - The company has received six product approvals from the National Medical Products Administration and the U.S. Food and Drug Administration, generating significant sales revenue [2] - This demonstrates Changfeng Pharmaceutical's capabilities in clinical development, production, regulatory affairs, and commercialization [2] Group 3 - ICBC International is a wholly-owned subsidiary of Industrial and Commercial Bank of China in Hong Kong, providing a range of financial services including corporate financing and market research [3] - The company leverages its parent bank's strong brand, financial strength, and extensive client base to serve both domestic and international capital markets [3] - ICBC International offers market research services covering macroeconomics, international financial markets, and key industries such as healthcare [3]
工银国际助力长风药业（2652.HK）成功完成香港上市项目